NCT05444374View on ClinicalTrials.gov

A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2025

Conditions

Cervical Cancer

Interventions

DRUG

Serplulimab

Recombinant anti-PD-1 humanized monoclonal antibody injection

DRUG

Bevacizumab

Humanized anti-VEGF monoclonal antibody injection

Trial Locations (4)

610000

Sicchuan Cancer Hospital, Chengdu

Unknown

Harbin Medical University Cancer Hospital, Harbin

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hunan Cancer Hospital, Changsha

All Listed Sponsors

lead

Sichuan Cancer Hospital and Research Institute

OTHER

NCT05444374 - A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter